Multifocal diffractive add-on IOL suitable alternative

Article

Multifocal diffractive add-on IOL is a suitable alternative to standard multifocal IOLs for sulcus fixation.

Multifocal diffractive add-on IOL is a suitable alternative to standard multifocal IOLs for sulcus fixation.

The prospective controlled clinical trial, led by Dr Jens Schrecker, Department of Ophthalmology, Saarland University, Homburg/Saar, Germany, included 65 eyes of 37 patients.

Of the patients studied, 34 eyes of 20 patients underwent phacoemulsification and implantation of a monofocal IOL in the capsular bag and an additional aberration-free diffractive IOL in the ciliary sulcus. The remaining 31 eyes of 17 patients were fitted with an aberration-correcting diffractive posterior chamber IOL.

Outcome measurements included uncorrected and distance-corrected distance, intermediate, and near visual acuities; contrast sensitivity and defocus curve were performed three months postoperatively.

There were no complications with cataract surgery, IOL implantation or the postoperative course. There were no significant differences in uncorrected and distance-corrected distance, intermediate, or near visual acuities between the two groups.

In both groups the median uncorrected distance visual acuity was 0.00 logMAR uncorrected near visual acuity was 0.10 logMAR. Contrast sensitivity testing was significantly better in the multifocal add-on IOL group, namely at spatial frequencies over 1.5 cycles per degree. The overall visual performance with a multifocal diffractive add-on IOL was equivalent to that obtained with the multifocal diffractive PC IOL.

The abstract can be viewed in the latest edition of the Journal of Cataract and Refractive Surgery.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.